chevron_leftBack
As of 24 April 2025, Nanobiotix S.A. has a market cap of $158.6M USD, ranking #18357 globally and #256 in France. It ranks #1828 in the Healthcare sector, and #530 in the Biotechnology industry.
Key Stats
Market Cap
$158.6MUSD
139.37M EUR
Enterprise Value
$159.26MUSD
140.53M EUR
Revenue (TTM)
-$8.18MUSD
-7.19M EUR
EBITDA (TTM)
-$76.68MUSD
-67.67M EUR
Net Income (TTM)
-$77.53MUSD
-68.13M EUR
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Biotechnology
CEO
Laurent Levy
open_in_new
Employees
108
Founded
2003
Website
nanobiotix.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| -1.4% | -2.3% | -13% | -7.5% | -36% | -45% |
Upcoming Earnings
Earnings Date
Fri, Apr 25
Tomorrow
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
NANO
Nanobiotix SA
ISIN: FR0011341205
Shares Out.:
Shares Outstanding:
47.111M1
Shares Float:
45.833M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
BA:
Barron's:
MS:
Morningstar:
|
2.90 EUR | |
|
0QAV
Nanobiotix SA
ISIN: FR0011341205
|
2.99 EUR | |
|
NASDAQ
MIC: XNAS
|
NBTX
Nanobiotix SA ADR
ISIN: US63009J1079
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
NQ:
NASDAQ:
BA:
Barron's:
MS:
Morningstar:
|
3.29 USD |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About Nanobiotix S.A.
Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is based in Paris, France.
